Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ATYR stock, giving a Buy rating on August 12.

Faisal Khurshid has given his Buy rating due to a combination of factors that suggest a promising outlook for aTyr Pharma despite recent controversies. The recent data from Kinevant’s failed Phase 2 study of namilumab in pulmonary sarcoidosis showed a strong placebo effect, which could be seen as a negative indicator for aTyr Pharma’s EFZO-FIT study. However, Khurshid believes that the differences in trial design and patient populations between the two studies limit the applicability of these results to aTyr Pharma’s situation.
Khursid points out that the EFZO-FIT study involves a more steroid-dependent patient population and employs a more aggressive steroid tapering protocol compared to the RESOLVE-LUNG study. This could potentially result in a lower placebo effect in EFZO-FIT, making the study’s outcomes more reliable. Despite the potential for controversy, Khurshid maintains a positive outlook on aTyr Pharma due to the high-risk, high-reward nature of their setup, which could lead to significant gains if successful.

In another report released on August 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.